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PURPOSE: To present the more frequent associations found in autopsies of immunocompromised patients who developed secondary
interstitial pneumonia as well as the risk of death (odds ratio) in having specific secondary interstitial pneumonia according to the
cause of immunocompromise.
METHOD: From January 1994 to March 2004, 17,000 autopsies were performed at Hospital das Clínicas, São Paulo University
Medical School. After examining the pathology report review, we selected 558 of these autopsies (3.28%) from patients aged 15
years or more with primary underlying diseases who developed radiologically diffuse infiltrates of the lung during their hospital
course and died after secondary interstitial pneumonia (bronchopneumonia, lobar pneumonia, interstitial pneumonia, diffuse
alveolar damage, pulmonary recurrence of underlying disease, drug-induced lung disease, cardiogenic pulmonary edema, or
pulmonary embolism). Histology slides were reviewed by experienced pathologists to confirm or not the presence of secondary
interstitial pneumonia. Statistical analysis included the Fisher exact test to verify any association between histopathology and the
cause of immunocompromise; a logistic regression was used to predict the risk of death for specific histological findings for each
of the independent variables in the model.
RESULTS: Secondary interstitial pneumonia was histologically represented by diffuse interstitial pneumonitis ranging from
mild nonspecific findings (n = 213) to a pattern of diffuse alveolar damage (n = 273). The principal causes of immunocompromise
in patients with diffuse alveolar damage were sepsis (136 cases), neoplasia (113 cases), diabetes mellitus (37 cases), and
transplantation (48 cases). A high risk of death by pulmonary edema was found for patients with carcinoma of colon. Similarly, in
patients with lung cancer or cachexia, A high risk of death by bronchopneumonia (OR = 3.6; OR = 2.6, respectively) was found.
Pulmonary thromboembolism was associated with an appreciable risk of death (OR = 2.4) in patients with arterial hypertension.
The risk of death was also high in patients presenting hepatic cancer (OR = 2.5) or steroid therapy (OR = 2.4) who developed
pulmonary hemorrhage as the histological pattern of secondary interstitial pneumonia . The risk of death by lung metastasis was
also elevated (OR = 1.6) for patients that were immunosuppressed after radiotherapy.
CONCLUSION: Patients with secondary immunosuppression who developed secondary interstitial pneumonia during treatment
in hospital should be evaluated to avoid death by diffuse alveolar damage, pulmonary edema, bronchopneumonia, lung hemorrhage,
pulmonary thromboembolism, or lung metastasis. The high-risk patients are those immunosuppressed by hematologic disease;
those under steroid treatment; or those with colon or hepatic carcinoma, cachexia, or arterial hypertension.
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INTRODUCTION
Acute pulmonary complications in an immuno-
compromised host are important causes of death in such pa-
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tients. Mortality has been reported to be higher than 40% to
50%, especially in patients who develop diffuse infiltrates.1,2
Pneumonia of bacterial, viral, or fungal origin is the most fre-
quent complication as a consequence of altered immunologi-
cal status of the host.3,4 Nevertheless, an immunocompromised
host can develop diffuse radiographic lung infiltrates without
evidence of active lower respiratory tract infection,5–7 a con-
dition that has been named secondary interstitial pneumonia.
The differential diagnosis of pulmonary disease in these pa-
tients includes infectious pneumonia, recurrence of underly-
ing disease, drug-induced lung disease, diffuse alveolar dam-
age, as well as unrelated processes such as cardiogenic pul-
monary edema or pulmonary embolism, or any combination
of these.8–10 Prompt investigation and diagnosis are essential
for improving the chances of patient survival.11,12 Clinical and
radiographic findings of acute pulmonary complications in the
immunocompromised host are nonspecific,5-7,13 and computed
tomography has been shown to be useful in the assessment
of these patients,5 mainly to assist in guiding biopsy. In this
context, the complexity of the clinical presentations turns di-
agnosis by the clinician into a constant challenge. In spite of
recent advances, most types of diagnostic support are still ex-
pensive. Not infrequently, the clinician initiates treatment, try-
ing to avoid rapid progression of the disease or more invasive
procedures. It is thus important to know the main causes of
death in this population to establish correct prophylactic ac-
tions, which are the cheaper and more intelligent ways to pre-
vent secondary interstitial pneumonia or the eventual indica-
tion for lung biopsy.14
The aim of this paper is to present the most frequent
associations found in autopsies of immunocompromised
patients who developed secondary interstitial pneumonia
as well as the risk of death (odds ratio) in having specific
secondary interstitial pneumonia according to the cause of
immunocompromise.
MATERIALS AND METHODS
Patients and Autopsies: From January 1994 to March
2004, 17,000 autopsies were performed at Hospital das
Clínicas, São Paulo University School of Medicine. After
examining the pathology report review, we selected 558 of
these autopsies (3.28%) from patients aged 15 years or
more with primary underlying diseases who developed
radiologically diffuse infiltrates of the lung during their
hospital course and died after secondary interstitial pneu-
monia (bronchopneumonia, lobar pneumonia, interstitial
pneumonia, diffuse alveolar damage, pulmonary recurrence
of underlying disease, drug-induced lung disease,
cardiogenic pulmonary edema, or pulmonary embolism).
The rapid and fatal clinical course was marked by progres-
sive respiratory failure and did not allow a pathological
evaluation of lung biopsies or bronchoalveolar lavage speci-
mens. Complete autopsies were performed in all cases. Tis-
sue samples were taken from all organs, including from
each lobe of both lungs. They were immediately fixed in
10% phosphate-buffered formaldehyde solution and embed-
ded in paraffin. Serial sections were cut (3 mm),
deparaffinized, and tissues were routinely processed. In all
cases, staining with hematoxylin and eosin was done for
histological examination, silver stains or mucicarmine for
Pneumocystis and fungi, Ziehl-Neelsen stain for mycobac-
terium, and Gram stains for bacteria.
Histopathology: Histology slides from the autopsies
were reviewed by experienced pathologists to confirm the
presence or not of secondary interstitial pneumonia, accord-
ing to the following patterns:
• Acute or chronic interstitial pneumonia, defined as a
thickened interstitium infiltrated by neutrophils and
macrophages (acute) or lymphocytes and plasmocytes
(chronic) in uniform temporal appearance;
• Diffuse alveolar damage, defined as interstitial acute
inflammation, with edema and neutrophils in uniform
temporal appearance and diffuse distribution; alveolar
collapse and hyaline membranes are also present.
• Pulmonary recurrence of underlying disease,
• Pulmonary edema, defined as proteinaceous intra-alveo-
lar transudate
• Pulmonary hemorrhage, defined as alveolar spaces con-
taining red cells
• Pulmonary thromboembolism, defined as arterial or ve-
nous occlusion by thrombi
Statistical Analysis: First analysis included the verifi-
cation of association between histopathology and
immunocompromise causes and was done using the Fisher
exact test. For this purpose, neoplasia cases were stratified
according to localization in the pancreas, liver, stomach,
esophagus, lung, breast, blood, colon, or nervous system.
Transplantation was equally stratified according to the af-
fected organ—in bone marrow, kidney, or liver. We then
performed a logistic regression analysis to predict the risk
of death for specific histological findings and to estimate
the odds ratios for each of the independent variables in the
model. We considered results with P values of less than
0.05 to be statistically significant.
RESULTS
Patient gender was 54.3% male and 45.7% female. Pa-
tient ages ranged from 15 to 91 years (median 51). The
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primary underlying diseases of the 558 patients with dif-
fuse pulmonary infiltrates included cancer (266 cases,
48%), sepsis (266 cases, 48%), transplantation (80 cases,
14%), diabetes mellitus (73 cases, 13%), chemotherapy (46
cases, 8.2%), steroid treatment (40 cases, 7.2%), malnu-
trition (26 cases, 5%), and radiotherapy (12 cases, 2.2%).
On histological examination, the lungs showed the most
evident lesions. Thus, secondary interstitial pneumonia that
developed during treatment in the hospital was histo-
logically represented by diffuse alveolar damage, primary
or metastatic lung cancer, cardiogenic pulmonary edema,
and pulmonary thromboembolism. Two hundred and sev-
enty three cases (49%) presented diffuse alveolar damage,
92 (16%) cardiogenic pulmonary edema, 72 (13%) bron-
chopneumonia, 62 (11%) pulmonary thromboembolism, 40
(7%) pulmonary hemorrhage, and 17 (4%) cases presented
primary or metastatic lung cancer (Figure 1).
Among the patients who developed diffuse alveolar
damage, we found viral inclusions in 17 cases, all of which
were associated with cytomegalovirus; fungi infection in
11 cases, associated with Aspergillus sp (n = 9), Crypto-
coccus sp (n = 1), and Pneumocystis carinii (n = 1) (Fig-
ure 2). Tuberculosis was found in 9 cases of diffuse alveo-
lar damage. The principal causes of immunocompromise
in patients with diffuse alveolar damage were sepsis (136
cases), neoplasia (113 cases), diabetes mellitus (37 cases),
and transplantation (48 cases). Chemotherapy and radio-
therapy were done in 25 and 8 cases, respectively. Twenty-
eight patients received steroid treatment, and 24 patients
had cachexia. It is important to emphasize that more than
1 type of immunocompromise might be present in the same
patient. After comparing all of these associations, we found
that the highest risk for dying from diffuse alveolar dam-
age was found in patients with hematological neoplasia or
under steroid treatment (Table 1). The same was found for
pulmonary edema bronchopneumonia, pulmonary throm-
boembolism, pulmonary hemorrhage, and primary or meta-
static lung cancer. A high risk of death by pulmonary edema
was found for patients with carcinoma of colon (Table 1).
Table 1 - Results of the logistic regression used to predict the risk of death (odds ratio) in patients with SIP, according to
the underlying disease
Variable B SE Wald Sig Exp (B)
DAD
Steroid treatment 1.0229 0.3739 7.4834 0.006 2.7811
Hematological disease 0.6201 0.3014 4.2321 0.03 1.8592
EDEMA
Colon carcinoma 0.9647 0.5331 3.2755 0.05 2.6241
BCP
Lung cancer 1.2830 0.5909 4.7139 0.02 3.6075
Caquexia 0.9619 0.4826 3.9724 0.04 2.6167
THROMBOEMBOLISM
Systemic hypertension 8901 0.4084 4.7516 0.02 2.4355
LUNG HEMORRHAGE
Hepatic cancer 0.9202 0.5101 3.2540 0.05 2.5098
Steroid therapy 0.8791 0.4025 4.7690 0.02 2.4086
LUNG METASTASIS
Radiotherapy 0.4934 0.6764 0.5322 0.04 1.6379
SIP = secondary interstitial pneumonia; DAD = diffuse alveolar disease
Figure 1 - Secondary interstitial pneumonia / diffuse alveolar damage in
immunocompromised patients: (A) diffuse alveolar damage, showing a
homogeneous distribution of the inflammatory process and hyaline
membranes; (B) cardiogenic pulmonary edema, showing the proteinaceous
intra-alveolar transudate; (C) diffuse alveolar damage in patients who
developed concomitant bronchopneumonia, showing the numerous
neutrophils inside of the alveolar space; (D) pulmonary thromboembolism,
showing the significant vascular occlusion; (E) pulmonary hemorrhage,
showing alveolar spaces containing red cells; and (F) a case with primary
lung cancer. Hematoxylin & eosin X 200 (panels A, D), X 100 (panels B,
E), and X 50 (panels C, F).
72
CLINICS 2007;62(1):69-76Autopsy-proven causes of death in lungs of patients immunocompromised
Terrabuio Junior AA et al.
Similarly, in patients with lung cancer or cachexia, the risk
of death by bronchopneumonia as determined histologically
was high (OR = 3.6; OR=2.6, respectively) . Pulmonary
thromboembolism, as determined histologically, was asso-
ciated with an appreciable risk of death (OR = 2.4) in pa-
tients with arterial hypertension. Of interest was the high
risk of death for patients with hepatic cancer (OR = 2.5)
or steroid therapy (OR = 2.4) who developed pulmonary
hemorrhage as the histological pattern of secondary inter-
stitial pneumonia . Equally interesting was the elevated risk
of death by lung metastasis (OR = 1.6) for patients that
were immunosuppressed after radiotherapy.
DISCUSSION
Conditions that contribute to the requirement for specific
histopathological and etiological criteria for definitive diag-
nosis in patients with immunosuppression are as follows: 1)
the nonspecificity of clinical and radiological findings, which
are common features for immunosuppressed patients who
develop pulmonary involvement during the course of their
disease; and 2) co-infections caused by other endemic patho-
gens in Brazil, such as fungi and tuberculosis.2,6,16-20 The high
cost for special techniques, such as molecular methods, still
poses a problem in developing countries.
The above-mentioned considerations prompted us to
carry out this study using histopathology of autopsy cases.
In doing so, we tried to verify the causes of death in the
population of immunocompromised patients who developed
secondary interstitial pneumonia .
In this series of adult patients (median age, 51 years),
men and women had similar prevalences of secondary in-
terstitial pneumonia . We found that the primary underly-
ing diseases of the 558 patients with diffuse pulmonary in-
filtrates included cancer (48%), sepsis (48%), transplanta-
tion (14%), diabetes mellitus (13%), chemotherapy (8.2%),
steroid treatment (7.2%), malnutrition (5%) and radio-
therapy (2.2%). A similar distribution was found by Juric
et al in 3117 autopsies.21 They found that the most com-
mon causes of death were cardiovascular diseases (40.9%),
followed by malignancies (25.2%) and infections (12.9%).
Among all cardiovascular diseases, myocardial infarction
was the most frequently diagnosed (17.9%) but it should
be noted that it was misdiagnosed by clinicians in 16.5%
of the cases. Incorrectly diagnosed malignancies were
found in only 5.7% of the cases; hematological and lym-
phoid malignancies (48.8%) were the most common neo-
plasms and were usually confirmed before death. Infections
were found in 46.9% of all autopsies. Bacterial pneumonias
and peritonitis were overlooked in 67.5% and 23.5% of the
cases, respectively, in which they existed together with an-
other serious condition.
On autopsy, we found that in patients with secondary
immunosuppression who developed secondary interstitial
pneumonia during treatment in hospital, the lungs were the
site with the most evident lesions that were directly respon-
sible by death. These patients died from diffuse alveolar
damage, primary or metastatic lung cancer, cardiogenic
pulmonary edema, or pulmonary thromboembolism.
The most prevalent autopsy finding as cause of second-
ary interstitial pneumonia in patients with immunosuppres-
sion was diffuse alveolar damage, identified in 273 cases.
Thus, it is important to emphasize 2 observations made in
this study regarding diffuse alveolar damage. The first is the
association of this type of damage with patients under me-
chanical ventilation at the time of death, thus raising the
question of whether diffuse alveolar damage could be sec-
ondary to mechanical ventilation injury and not related to
immunodeficiency. This very important question probably
will not be answered by this study because our review was
performed on pathologic reports after necropsy, where the
information about mechanical ventilation is not is present
among the data. With respect to the question of whether dif-
Figure 2 - Histological examination of lungs with diffuse alveolar damage
show viral inclusions and fungi infection: (A) diffuse alveolar damage,
showing notable amounts of viral inclusions; (B) detail of the
cytomegalovirus inclusion (arrows); (C) Fungi infection represented by
Aspergillus sp. (arrows); (D) detail of numerous Aspergillus sp. inside of
the alveolar space (stained with silver). (E) diffuse alveolar damage, showing
the presences of Cryptococcus sp. (arrows); (F) detail of this fungi stained
with mucicarmine; (G) Diffuse alveolar damage, showing infection by
Pneumocystis carinii inside the alveolar space; (F) detail of Pneumocystis
carinii (arrows) (stained with silver). Hematoxylin & eosin X 200 (panels
A, E), X 100 (panels C, G), and X 50 (panel B); Silver stain X 100 (panel
D), and X 50 (panel H); Mucicarmine stain X 50 (panel F).
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fuse alveolar damage could be secondary to mechanical ven-
tilation injury and not related to immunodeficiency, our an-
swer is yes, because most of the patients undergoing me-
chanical ventilation already have diffuse alveolar damage.
In addition, the morphological pattern of diffuse alveolar
damage is different when secondary to barotraumas; in the
case of barotrauma, this damage is almost always represented
by thin hyaline membranes, while in case of immunodefi-
ciency, all of the diffuse alveolar damage cases presented
thicker hyaline membranes and had notable changes in al-
veolar septae as well as extensive alveolar collapse. Brun-
Buisson et al22 studied the epidemiology and outcome of
acute lung injury in European intensive care units (ICUs).
They found that acute lung injury occurred in 463 (7.1%)
of 6522 admissions and 16.1% of all mechanically ventilated
patients; 65.4% cases occurred on ICU admission.
The second important observation about diffuse alveo-
lar damage is the association with infectious etiology rep-
resented by fungi, citomegalo, and tuberculosis. Among the
fungi, Aspergillus sp was the most prevalent. Association
between Aspergillus and diffuse alveolar damage was simi-
larly found in immunosuppressed patients by other au-
thors.23–29 Another important association was found between
diffuse alveolar damage and citomegalo. In our study, 17
immunosuppressed patients presented diffuse alveolar dam-
age and citomegalo viral inclusions, thus confirming the
prevalence of citomegalo in immunosuppressed patients,
who are usually very sick patients and are kept in the ICU
for long periods; it is possible that in these patients, the
diffuse alveolar damage is not secondary to the cytomeg-
alic infection.30–36
Diffuse alveolar damage was a prevalent morphologi-
cal finding in patients immunocompromised by sepsis, neo-
plasia, diabetes mellitus, or transplantation. As expected,
all of these conditions are very prevalent in a series of
immunosuppressed patients, probably contributing to their
deaths. Diffuse alveolar damage was also a final morpho-
logical event in 2 immunosuppressed patients who under-
went chemotherapy and radiotherapy but were not under-
going that therapeutic regimen at the time of the death. This
finding is very important because if they were under tho-
racic radiotherapy or under the effects of drugs, the inter-
pretation of the pulmonary findings was completely differ-
ent, as previously reported by Camus and Rossi.37,38 Also
expected was the prevalence of diffuse alveolar damage as
the cause of death in patients with cachexia, which was fre-
quently observed in series of patients with immunodefi-
ciency. However, the highest risk of death by diffuse al-
veolar damage was found in patients with hematological
diseases or under steroid treatment, in agreement with pre-
viously reported data.39-46
In our study, pulmonary edema was the second most
important cause of death, with highest risk for patients with
carcinoma of colon. This finding is very similar to that
found by Hoelz et al in their study concerning
morphometric differences in pulmonary lesions in primary
and secondary ARDS.47
We found that pulmonary thromboembolism as the mor-
phological pattern for secondary interstitial pneumonia oc-
curred in 11% of patients with arterial hypertension, an ap-
preciable risk of death. Madani et al48 carried out a retro-
spective review of all postmortem reports during the period
1991 to 2000 at King’s College Hospital, London. They
found that during that 10-year period, 16,104 deaths oc-
curred, and 6,833 (42.4%) necropsies were performed. The
outcome occurrence, fatal pulmonary embolism, was re-
corded as cause of death in 265 cases (3.9% of all necrop-
sies; 5.2% of adult cases). No deaths from pulmonary em-
bolism occurred in patients under 18 years of age; 80.0%
occurred in patients older than 60 years. Of the fatal em-
boli, 214 of 265 (80.8%) occurred in patients who had not
undergone recent surgery. Of these patients, 110 (51.4%) had
suffered an acute medical illness in the 6 weeks before death,
most often an acute infectious episode (26 cases).
Of interest in our study was the high prevalence of pa-
tients presenting hepatic cancer or steroid therapy who de-
veloped fatal pulmonary hemorrhage as the histological
pattern of secondary interstitial pneumonia . Parambil et
al.49 studied causes and presenting features of pulmonary
infarctions in 43 cases identified by surgical lung biopsy.
The underlying cause was identifiable in 31 cases (72%)
based on a review of clinical, laboratory, radiologic, and
histopathologic data. The 2 most common causes were pul-
monary thromboembolism (18 cases, 42%) and pulmonary
infections (5 cases, 12%). Thromboembolic pulmonary
infarctions typically presented as solitary or multiple nod-
ules located in the subpleural regions. Other causes in-
cluded diffuse alveolar damage in 2 cases (5%), pulmonary
torsion in 2 cases (5%), and 1 case each of lung cancer,
amyloidosis, embolotherapy, and catheter embolism. In 12
cases (28%), the underlying cause was not directly identi-
fiable but was probably due to previous pulmonary throm-
boembolism.
We conclude that patients with secondary immunosup-
pression who develop secondary interstitial pneumonia dur-
ing treatment in the hospital should be evaluated to avoid
death cause by diffuse alveolar damage, pulmonary edema,
bronchopneumonia, lung hemorrhage, pulmonary throm-
boembolism, or lung metastasis. The high-risk patients are
those immunosuppressed by hematological disease; who are
under steroid treatment; or who have colon or hepatic car-
cinoma, cachexia, or arterial hypertension.
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RESUMO
Terrabuio Junior AA, Parra ER, Farhat C, Capelozzi VL.
Causas de óbito por pneumonia intersticial secundária em
autópsias pulmonares de pacientes imunocomprometidos.
Clinics. 2007;62(1):69-76.
OBJETIVO: Apresentar as associações mais freqüentes
encontradas em autópsias de pacientes imunossuprimidos
que desenvolveram pneumonia intersticial secundária bem
como o risco de óbito (Odds Ratio) de desenvolver PIS
associada à causa da imunossupressão.
MÉTODO: De janeiro de 1994 a março de 2004, 17000
autópsias foram realizadas no Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo. A partir
da revisão dos laudos patológicos foram selecionados 558
destas autópsias (3,28%) de pacientes com 15 anos de idade
ou mais, com alguma doença de base que desenvolveu um
infiltrado pulmonar radiologicamente difuso durante o curso
da hospitalização e que depois foi para óbito com pneumo-
nia intersticial secundária (broncopneumonia, pneumonia lo-
bar, pneumonia intersticial, dano alveolar difuso, doença
pulmonar recorrente, doença pulmonar induzida por drogas,
edema pulmonar cardiogênico e embolismo pulmonar). As
lâminas histológicas foram revisadas por patologistas
experientes para confirmar ou não a presença de pneumonia
intersticial secundária. A análise estatística incluiu o “Teste
exato de Fisher” para verificar associação entre a
histolopatologia e causa de imunocomprometimento; e
regressão logística para predizer o risco de óbito por achados
histológicos específicos para cada variável independente do
modelo.
RESULTADOS: A pneumonia intersticial secundária foi
representada histológicamente por pneumonite intersticial
difusa variando de características não especificas leves
(n=213) ao padrão histológico de dano alveolar difuso
(n=273). A principal causa de imunossupressão nos
pacientes com dano alveolar difuso foi sepse (136 casos),
neoplasia (113 casos), diabetes melito (37 casos) e
transplantados (37 casos). O maior risco de morte por
edema pulmonar foi encontrado nos pacientes com carci-
noma de cólon. Da mesma forma, nos pacientes com câncer
pulmonar ou cachexia ocorreu um alto risco de morte
(OR=3.6; OR=2.6, respectivamente) por broncopneumonia.
O tromboembolismo pulmonar ofereceu um importante
risco de morte (OR=2.4) nos pacientes com hipertensão ar-
terial. Observou-se também risco de morte por câncer
hepático (OR=2.5) ou terapia esteroidea (OR=2.4) nos
pacientes que desenvolveram hemorragia pulmonar com
padrão histológico de pneumonia intersticial secundária. Da
mesma forma houve alto risco de morte por metástase
pulmonar (OR= 1.6) nos pacientes imunossuprimidos após
radioterapia.
CONCLUSÃO: Pacientes com imunossupressão secundária
que desenvolveram pneumonia intersticial secundária durante
o tratamento dentro do hospital podem ser avaliados para
evitar como evento final o dano alveolar difuso, o edema
pulmonar, a broncopneumonia, a hemorragia pulmonar, o
tromboembolismo pulmonar e a metástase pulmonar. Os
pacientes com aumento de risco são aqueles imunossuprimidos
por doença hematológica, sob tratamento com esteroides,
carcimona hepático, cachexia e hipertensão.
UNITERMOS: Autópsias. Pneumonia intersticial
secundária. Pacientes imunocomprometidos. Dano alveo-
lar difuso.
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